Table 1

Baseline patient characteristics

Statin naïve patients
n=150
p Value*
RA/AS/PsA
Statin users
n=47
p Value*
RA/AS/PsA
Statin naïve vs statin users
p value
Age median (IQR)61 (56.0, 67.0)0.0165.0 (60.0, 70.0)0.0040.01
Sex male/female n (%)61/89 (40.7/59.3)<0.00122/25 (46.8/53.2)0.060.46
Disease duration median (IQR)18 (6.0, 26.0)0.00125.0 (16.0, 34.5)0.040.001
CV risk factors
 Smoke n (%)28 (18.7)0.2910 (21.3)0.260.69
 BMI mean±SD26.0±4.00.8926.3±5.20.410.78
 TC (mmol/L) mean±SD6.24±1.160.754.97±1.070.56<0.001
 HDL-c (mmol/L) mean±SD1.68±0.490.041.68±0.680.040.99
 TG (mmol/L) median (IQR)1.22 (0.89, 1.69)0.691.24 (0.92, 1.80)0.100.94
 LDL-c (mmol/L) mean±SD3.92±0.990.222.68±0.830.12<0.001
 BP systolic (mm Hg) mean±SD143.9±20.30.83150.6±20.01.000.05
 BP diastolic (mm Hg) mean±SD85.0±10.90.5185.9±10.90.900.62
Comorbidities n (%)
 HT97 (64.7)0.4341 (87.2)0.160.003
 Diabetes10 (6.7)0.9515 (31.9)0.92<0.001
 CV disease48 (32.0)0.2427 (57.4)0.53<0.001
 Combined dyslipidaemia6 (4.0)0.013 (6.4)0.030.50
 Hyperlipidaemia85 (56.7)0.618 (17.0)0.27<0.001
Biomarkers mean±SD
 ESR (mm/h)17.8±16.10.3418.4±13.90.420.82
 CRP (mg/L) median (IQR)3.0 (1.0, 7.5)0.243.0 (1.0, 7.0)0.310.42
 AST (U/L)27.7±9.20.7132.2±20.20.940.05
 ALT (U/L)30.1±18.70.0837.3±35.00.940.07
 CK (U/L)87.3±48.00.00298.0±48.40.670.22
Medication n (%)
 Prednisolone39 (26.0)0.0112 (25.5)0.090.95
 NSAIDs56 (37.3)0.2617 (36.2)0.720.81
 sDMARDs69 (46.0)<0.00117 (36.2)0.28<0.001
 bDMARDs41 (27.3)0.269 (19.1)0.39<0.001
  • *p Value describes comparison between patients with RA, AS and PsA.

  • ALT, alanine aminotransferase; AS, ankylosing spondylitis; AST, aspartate aminotransferase; bDMARDs, biological disease modifying antirheumatic drugs; BMI, body mass index; BP, blood pressure; CK, creatine kinase; CRP, C reactive protein; CV disease, cardiovascular disease (angina pectoris, myocardial infarction, percutaneous coronary intervention, heart surgery, transitory ischaemic attack, stroke, peripheral artery disease); ESR, erythrocyte sedimentation rate; HDL-c, high density lipoprotein cholesterol; HT, hypertension; LDL-c, low density lipoprotein cholesterol; NSAIDs, non-steroid anti-inflammatory drugs; PsA, psoriatic arthritis; RA, rheumatoid arthritis; sDMARDs, synthetic disease modifying antirheumatic drugs; TC, total cholesterol; TG, triglycerides.

  • Hyperlipidaemia: TC ≥6.0 mmol/L. Combined dyslipidemia: TG ≥2.0 mmol/L and HDL-c ≤1.0 mmol/L.